drugset
drugset / Trial / NCT04472767

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

NCT04472767 ↗

Phase 2 Recruiting 35 enrolled University of California, Irvine Exelixis · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for curative intent treatment.

Timeline

Start
2020-08-07
Primary completion
2026-10-01
Completion
2027-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabozantinib Small molecule 40 mg Oral
Subject Ipilimumab Monoclonal antibody 1 mg/kg Intravenous
Subject Nivolumab Monoclonal antibody 480 mg Intravenous

Indications

hepatocellular carcinoma